US2019000542A1PendingUtilityA1
Systems and methods for ablative treatment of irritable bowel disease
Est. expiryJun 29, 2037(~11 yrs left)· nominal 20-yr term from priority
A61N 7/022A61B 2018/00214A61B 2018/1497A61B 18/1492A61B 2018/00714A61B 2018/00482A61B 2018/00761A61B 2018/0016A61B 18/1477A61B 2018/00702A61B 2018/0212A61B 2018/00494A61B 2018/00577A61M 25/0082A61B 18/24A61B 2018/00434A61B 18/042A61B 2218/007A61B 2018/00636
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods, systems, and devices are described for treating diseases of the gastrointestinal tract, including ulcerative colitis, by delivering ablative energy to a tissue surface of the gastrointestinal tract and ablating the tissue to a controlled depth. Ablating the tissue may include removing a biofilm layer or coagulating tissue.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for treating ulcerative colitis in a patient, the method comprising:
delivering energy to a tissue surface of a tissue within the large intestine of the patient; and ablating the tissue with the delivered energy to a controlled depth.
2 . The method of claim 1 , wherein ablating the tissue comprises removing a biofilm layer at least partially covering the tissue surface.
3 . The method of claim 1 , wherein ablating the tissue comprises removing a biofilm layer at least partially penetrating below the tissue surface.
4 . The method of claim 1 , wherein ablating the tissue comprises coagulating tissue within the mucosal layers of the tissue.
5 . The method of claim 1 , wherein ablating the tissue comprises coagulating tissue below the mucosal layers of the tissue.
6 . The method of claim 1 , wherein ablating the tissue comprises ablating under conditions selected to initiate regrowth of healthy mucosal tissue.
7 . The method of claim 1 , wherein ablating the tissue comprises defunctionalizing degenerated arborized nerve fibers within the tissue.
8 . The method of claim 1 , wherein ablating the tissue to a controlled depth comprises controlling a duration of the delivery of energy.
9 . The method of claim 1 , wherein ablating the tissue to a controlled depth comprises controlling an energy density of the delivered energy.
10 . The method of claim 1 , wherein ablating the tissue to a controlled depth comprises controlling a temperature of the tissue surface during the delivery of energy.
11 . The method of claim 1 , wherein delivering energy to the tissue surface comprises delivering energy into crypts within the tissue.
12 . The method of claim 1 , wherein delivering energy to the tissue surface comprises delivering energy to a fully circumferential portion of the large intestine.
13 . The method of claim 1 , wherein delivering energy to the tissue surface comprises delivering energy to a partially circumferential portion of the large intestine.
14 . The method of claim 1 , wherein delivering energy to the tissue surface comprises at least partially filling a volume of a section of the large intestine with a plasma.
15 . The method of claim 1 , wherein the energy comprises bipolar radiofrequency energy, monopolar radiofrequency energy, saline-mediated plasma radiofrequency energy, or a combination thereof.
16 . The method of claim 1 , wherein the energy comprises ultrasonic energy.
17 . The method of claim 1 , wherein the energy comprises a thermal plasma or a non-thermal plasma.
18 . The method of claim 1 , wherein the energy comprises laser energy.
19 . The method of claim 1 , wherein the energy comprises cryothermal energy.
20 . The method of claim 1 , further comprising:
delivering a pharmaceutical substance to the tissue surface.Join the waitlist — get patent alerts
Track US2019000542A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.